Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.52 |
| ▸ | IKZF2 | Q9UKS7 | 6/20 | 0.47 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26609033 | 0.97 | CRBN (0.52) | CRBNIKZF2IKZF1IKZF3CSNK1A1 | |
| SCHEMBL26610091 | 0.96 | CRBN (0.54) | CRBNIKZF2IKZF1IKZF3CSNK1A1 | |
| SCHEMBL26609118 | 0.91 | CRBN (0.51) | CRBNIKZF2IKZF1IKZF3CSNK1A1 | |
| SCHEMBL26609621 | 0.90 | CRBN (0.57) | CRBNIKZF2IKZF1IKZF3CSNK1A1 | |
| SCHEMBL26687920 | 0.90 | CRBN (0.52) | CRBNIKZF2IKZF1IKZF3CSNK1A1 | |
| SCHEMBL26610349 | 0.90 | CRBN (0.50) | CRBNIKZF2IKZF1IKZF3 | |
| SCHEMBL26110514 | 0.89 | CRBN (0.56) | CRBNIKZF2IKZF1IKZF3CSNK1A1 | |
| SCHEMBL26608780 | 0.85 | IKZF2 (0.61) | CRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL26610621 | 0.85 | CRBN (0.52) | CRBNIKZF2IKZF1IKZF3CSNK1A1 | |
| SCHEMBL26609249 | 0.85 | CRBN (0.50) | CRBNIKZF2IKZF1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | claimed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | CSNK1A1, CSNK1D, CSNK1G1 | CRBN 2723/4885IKZF2 2228/4885IKZF1 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.